Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CCR1 | P32246 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4487454 | 1.00 | KMT2A (0.55) | KMT2ATSHRLMNACCR1MEN1 | |
| Trifluoroacetic Acid SCHEMBL5444973 | 0.94 | KMT2A (0.52) | KMT2ATSHRLMNACCR1MEN1 | |
| SCHEMBL10291933 | 0.82 | CCR1 (0.51) | KMT2ATSHRLMNACCR1POLB | |
| SCHEMBL13606408 | 0.81 | CCR1 (0.64) | KMT2ALMNACCR1ALDH1A1MAPT | |
| SCHEMBL4489756 | 0.78 | LMNA (0.50) | KMT2ATSHRLMNACCR1MEN1 | |
| SCHEMBL4489758 | 0.78 | LMNA (0.50) | KMT2ATSHRLMNACCR1MEN1 | |
| Trifluoroacetic Acid SCHEMBL4508906 | 0.77 | CCR1 (0.58) | KMT2ALMNACCR1ALDH1A1MAPT | |
| SCHEMBL4501206 | 0.77 | NPSR1 (0.48) | KMT2ALMNACCR1MEN1ALDH1A1 | |
| SCHEMBL4501202 | 0.77 | NPSR1 (0.48) | KMT2ALMNACCR1MEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4502717 | 0.76 | NPSR1 (0.48) | KMT2ALMNACCR1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609664-B2 | Piperazinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB CO. (US) | 2013-12-17 | — | — | US | disclosed |
| EP-1973880-B1 | PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20090298845-A1 | PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-03 | — | — | US | disclosed |
| US-7615556-B2 | Piperazinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298845-A1 | PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR2, CCR5, CCR1 | KMT2A 2333/4885TSHR 357/4885LMNA 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.